Bristol Myers Squibb is kicking off another initiative aimed at improving diversity in clinical research, this time focusing on trial participants with disabilities, a group the pharma titan says is severely underrepresented in research and often left out of discussions.

The newly announced Disability Diversity in Clinical Trials (DDiCT) program will see the drugmaker and Disability Solutions, a U.S. nonprofit dedicated to inclusion initiatives for people with disabilities, working together to deliver recommendations on improving trial access, engagement, enrollment speed and participation for this group.

Long-term, BMS says, the project’s goal is to develop and pilot trials that are accessible to the greatest variety of people with disabilities.

DDiCT is part of BMS’ broader inclusion and diversity health equity commitments it first made in August 2020. Those efforts will run until 2025, according to the company.